Cas:1061755-72-3 3,9-Diazaspiro[5.5]undecane-3-carboxylic acid, ethyl ester manufacturer & supplier

Chemical Name:3,9-Diazaspiro[5.5]undecane-3-carboxylic acid, ethyl ester

CAS.NO:1061755-72-3

Synonyms:3,9-Diazaspiro[5.5]undecane-3-carboxylic acid, ethyl ester

Molecular Formula:C₁₂H₂₂N₂O₂

Molecular Weight:226.31500

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:41.57000

Exact Mass:226.16800

LogP:1.87520

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3,9-Diazaspiro[5.5]undecane-3-carboxylic acid, ethyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3,9-Diazaspiro[5.5]undecane-3-carboxylic acid, ethyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,9-Diazaspiro[5.5]undecane-3-carboxylic acid, ethyl ester Use and application,3,9-Diazaspiro[5.5]undecane-3-carboxylic acid, ethyl ester technical grade,usp/ep/jp grade.

Related News: Rigosertib, Onconova��s lead candidate, is a proprietary Phase 3 small molecule. 3,9-Diazaspiro[5.5]undecane-3-carboxylic acid, ethyl ester manufacturer There’s still hope for this approach to treating Alzheimer’s disease despite the somewhat mixed results from this trial, said Rebecca Edelmayer, senior director of scientific engagement at the Alzheimer’s Association. 3,9-Diazaspiro[5.5]undecane-3-carboxylic acid, ethyl ester supplier There’s still hope for this approach to treating Alzheimer’s disease despite the somewhat mixed results from this trial, said Rebecca Edelmayer, senior director of scientific engagement at the Alzheimer’s Association. 3,9-Diazaspiro[5.5]undecane-3-carboxylic acid, ethyl ester vendor Inceptua has global operations with local offices across Europe, USA, and Asia 3,9-Diazaspiro[5.5]undecane-3-carboxylic acid, ethyl ester factory There’s still hope for this approach to treating Alzheimer’s disease despite the somewhat mixed results from this trial, said Rebecca Edelmayer, senior director of scientific engagement at the Alzheimer’s Association.